XNAS · Healthcare · Biotechnology
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-04 | Q1 2026 | -1.22 | -1.28 | -4.92% | $1.5M | ❌ Miss | -1.38% | +0.80% | -2.80% |
| 2026-02-12 | Q4 2025 | -1.20 | -1.37 | -14.17% | $864,000 | ❌ Miss | -0.88% | +11.67% | -0.37% |
| 2025-11-10 |
| Q3 2025 |
| -1.30 |
| -1.17 |
| +10.00% |
| $889,000 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-04 | Q2 2025 | -1.43 | -1.29 | +9.79% | $892,000 | ✅ Beat | — | — | — |
| 2025-05-06 | Q1 2025 | -1.25 | -1.58 | -26.40% | $865,000 | ❌ Miss | — | — | — |
| 2025-02-11 | Q4 2024 | -1.21 | -0.44 | +63.64% | $35.7M | ✅ Beat | — | — | — |
| 2024-11-05 | Q3 2024 | -1.42 | -1.01 | +28.87% | $602,000 | ✅ Beat | — | — | — |
| 2024-08-05 | Q2 2024 | -1.52 | -1.49 | +1.97% | $517,000 | ✅ Beat | — | — | — |
Showing last 8 quarters.